Bioshares 18th Biotech Summit Presentation
Released
Released
Announcement PDF
ASX Announcement
Ra c e t o P re s e n t a t t h e Bio s h a re s 18 t h Bio t e c h Su m m it
12 July 2024 – Race Oncology Limited (“Race”) is pleased to share a copy of the presentation that will be
presented to investors and industry colleagues at the Bioshares 18th Biotech Summit this week in
Fremantle, WA.
Race Executive Director, Dr Pete Smith will present from 5.30 to 5.50pm later today as part of Session 4:
Repurposing Existing Pharmaceuticals.
During his presentation, Pete will underscore the importance of cardiovascular toxicity caused by oncology
therapies and how it effects patients’ lives post treatment. He will also discuss the clinical history of Race’s
lead asset bisantrene, the development of the new RC220 bisantrene formulation, and Race’s clinical plans
for RC220 bisantrene.
The Race team looks forward to meeting with investors in attendance at the summit. For more on the
Bioshares 2024 Summit, please visit: https://www.bioshares.com.au/summit/18th-bioshares-biotechsummit-1?EventGuid=8d415f38-3333-4b9d-ae86-89de1692ba5d
A copy of the presentation is appended to this announcement.
-ENDS-
Ab o u t Ra c e O n c o lo g y (ASX: RAC)
Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated
mission to be at the heart of cancer care.
Race’s lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a rich and unique
clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well
characterised safety profile, and compelling clinical data demonstrating an anticancer effect and less
cardiotoxicity over certain anthracyclines, such as doxorubicin.
Race is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across
multiple oncology indications, with a clinical focus on anthracycline combinations, where we hope to
deliver cardioprotection and enhanced anti-cancer activity in solid tumours. Race is also exploring RC220
bisantrene as a low intensity treatment for acute myeloid leukaemia.
Race is investigating the effect of bisantrene on the m6A RNA pathway, following independent research
published by the City of Hope identifying bisantrene as a potent inhibitor of FTO (Fat mass and obesityassociated protein). Dysregulation of the m6A RNA pathway has been described in numerous peer
reviewed studies as a driver of a diverse range of cancers.
Race Oncology has collaborated with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School
of Medicine, University of Wollongong and University of Newcastle, and is actively exploring partnerships,
Race Oncology Ltd • ABN 61 149 318 749
L36, 1 Macquarie Place Sydney NSW 2000 • T. +61 2 8051 3043 • E. info@raceoncology.com • www.raceoncology.com
licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients
with cancer across the world.
Learn more at www.raceoncology.com.
If you have any questions on this announcement or any past Race Oncology announcements, please go to
the Interactive Announcements page in our Investor Hub https://announcements.raceoncology.com
Race encourages all investors to go paperless by registering their details with the Company’s share registry,
Automic Registry Services, at www.automicgroup.com.au.
Release authorised by:
Media contact:
Daniel Tillett, CEO
info@raceoncology.com
Jane Lowe +61 411 117 774
jane.lowe@irdepartment.com.au
Race Oncology Ltd • ABN 61 149 318 749
L36, 1 Macquarie Place Sydney NSW 2000 • T. +61 2 8051 3043 • E. info@raceoncology.com • www.raceoncology.com
J u l y
2 0 2 4
AT THE
HEART OF
CANCER CARE
Pete Smith PhD, Executive Director
Bioshares 2024
0
1
ASX: RAC | RACE ONCOLOGY LIMITED | ABN 61 149 318 749
NOT FINANCIAL PRODUCT ADVICE
C A R E
This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. Any securities described in this presentation have not been, and will not be, registered under the US Securities Act of 1933, as
amended (Securities Act) or the securities laws of any state or other jurisdiction of the United States and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the Securities Act and
applicable US state securities laws. This presentation may not be released to US wire services or distributed in the United States. The distribution of this presentation in other jurisdictions outside Australia may also be restricted by law and any such
restrictions should be observed.
C A N C E R
Statements in this presentation are made only as of the date of this presentation unless otherwise stated and the information in this presentation remains subject to change without notice. No representation or warranty, express or implied, is made as
to the fairness, accuracy or completeness of the information, opinions and conclusions contained in this presentation or any other information the Company or any other person otherwise provides to you.
O F
This presentation is not a prospectus, product disclosure statement or disclosure document for the purposes of the Corporations Act 2001 (Cth) (Corporations Act). It has not been lodged with the Australian Securities and Investments Commission, or
otherwise.
H E A R T
THIS IS NOT A PROSPECTUS
T H E
The material in this presentation has been prepared by Race Oncology Limited (ACN 149 318 749) (Company).
A T
Important Notice and Disclaimer
No attempt has been made to independently verify the information contained in this presentation. The information in this presentation is of a general nature and does not constitute financial product advice, investment advice or any recommendation.
Nothing in this presentation constitutes legal, financial, tax or other advice. The information in this presentation does not take into account your particular investment objectives, financial situation or needs, or those of any other person. You should
make your own assessment of an investment in the Company and should not rely on this presentation. In all cases, you should conduct your own investigations and analysis of the financial condition, assets and liabilities, financial position and
performance, profits and losses, prospects and business affairs of the Company and its business, and the contents of this presentation. You should seek legal, financial, tax and other advice appropriate to your jurisdiction.
THIS PRESENTATION DOES NOT CONSTITUTE AN OFFER OR ADVERTISEMENT
This presentation does not constitute an invitation, offer or recommendation to apply for or purchase Shares and does not contain any application form for Shares. This presentation does not constitute an advertisement for an offer or proposed offer of
Shares.
NO LIABILITY
The Company has prepared this presentation based on information available to it at the time of preparation, from sources believed to be reliable and subject to the qualifications in this presentation. No representation or warranty, express or implied, is
made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of the Company or its subsidiaries or affiliates or the directors,
employees, agents, representatives or advisers of any such party, nor any other person accepts any liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including without limitation, any
liability arising from fault or negligence on the part of the Company or its subsidiaries or affiliates or the directors, employees, agents, representatives or advisers of any such party.
FORWARD-LOOKING STATEMENTS
This presentation may contain forward-looking statements that are subject to risk factors associated with an oncology company. Forward looking statements can be identified by the use of forward-looking terminology, including, without limitation, the
terms “believes”, “estimates”, “anticipates”, “expects”, “predicts”, “intends”, “plans”, “goals”, “targets”, “aims”, “outlook”, “guidance”, “forecasts”, “may”, “will”, “would”, “could” or “should” or, in each case, their negative or other variations or
comparable terminology. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and
depend on circumstances that may or may not occur in the future and may be beyond the Company’s ability to control or predict which may cause the actual results or performance of the Company to be materially different from the results or
performance expressed or implied by such forward-looking statements. Forward looking statements are based on assumptions and are not guarantees or predictions of future performance. No representation is made that any of these statements or
projections will come to pass or that any forecast result will be achieved, nor as to their accuracy, completeness or correctness. Similarly, no representation is given that the assumptions upon which forward looking statements may be based are
reasonable.
2
A T
T H E
H E A R T
O F
C A N C E R
C A R E
Cancer
survivorship
3
A T
Cancer survivorship – life after treatment
T H E
Ageing
O F
C A N C E R
By 2023, there will be 22.5m cancer
survivors in the US 1 with a 37% increased
risk of cardiovascular disease for postchemotherapy patients 2
H E A R T
New specialties such as cardiooncology are focused on reducing
damage caused by treatments
C A R E
Clinician
interest
Cardiovascular toxicity is
permanent 4 and can be profound
for certain groups, e.g. children
1. Miller KD, et al. Cancer J Clin, 2022
2. Florido R, et al. J Am Coll Cardiol, 2022
Race.
Heart
damage
+ other
effects
Better
therapy =
longevity
A single dose of chemotherapy can
cause cardiotoxicity 3 and muscle
atrophy 4
3. Dillon HJ, et al. J Am Coll Cardiol, 2024
4. Mallard J, et al. J Cachexia Sarcopenia Muscle, 2024
4
A T
Chemotherapy needs improvement
T H E
H E A R T
O F
Issue – patients not given full
effective dose, and heart damage
with serious long-term health
consequences remains
Opportunity – if the cardiovascular
toxicity could be reduced, more
patients could be treated and
more effective regimens delivered
C A R E
Current solution – exclude use in
high-risk patients and limit
dosing of the drugs
C A N C E R
Anthracyclines* are the most widely
used class of chemotherapeutics.
They are highly effective, but can
cause permanent damage to
the cardiovascular system
“Cardiotoxicity, which includes heart failure, is
one of the main side effects limiting the use of
these effective therapies.”
Professor Aaron Sverdlov, University of Newcastle
* Approved anthracyclines include doxorubicin, daunorubicin, epirubicin, idarubicin and valrubicin
5
T H E
Ewing sarcoma
Advanced endometrial
cancer
Acute nonlymphocytic
leukemia
Soft tissue sarcoma
Uterine sarcoma
Acute myelogenous
leukemia
Bone sarcoma
Metastatic
hepatocellular cancer
Hodgkin's lymphoma
Thyroid sarcoma
Advanced renal cell
carcinoma
Non-Hodgkin's
lymphoma
Neuroblastoma
Thymomas & thymic
malignancies
Bladder cancer
Wilms tumor
Waldenstrom
macroglobulinemia
Breast cancer
Small cell lung
cancer
Ovarian cancer
Gastric carcinoma
Osteogenic sarcoma
Bronchogenic
carcinoma
AIDS-related Kaposi’s
sarcoma
Prostate cancer
C A R E
Acute lymphocytic
leukemia
C A N C E R
Other uses2, 3
O F
FDA approved uses2, 3
H E A R T
Global anthracycline usage1
A T
Global anthracycline chemotherapy use1
Multiple myeloma
1. Estimated number of anthracycline doses used per year – Triangle Insights (ASX Announcement: 14 April 2023)
2. Daunorubicin, doxorubicin, liposomal doxorubicin (Doxil), epirubicin, idarubicin, mitoxantrone, and valrubicin
3. Triangle Insights (ASX Announcement: 14 April 2023)
6
A T
T H E
H E A R T
O F
C A N C E R
C A R E
Clinical
development of
bisantrene
7
A T
Corporate snapshot
T H E
H E A R T
Race Oncology is an ASX-listed, clinical stage biopharmaceutical company with a dedicated mission to be at the
heart of cancer care.
O F
RAC
Share price
$1.70 1
Market capitalisation
Cash at bank
Debt
$289.52m 1
$16.2m 2
Nil
Enterprise value
$273.32m 1
Shares on issue
170,311,803 1
Options on issue
35,486,338 1
1. As at 5 July 2024
2. As at 31 March 2024
C A R E
ASX code
C A N C E R
Race 12-month trading history
Key data
Current Bonus & Piggyback Options Offer
On 22 November 2023, Race issued a 1 for 20 bonus and piggyback option series to
existing shareholders. The conversion of bonus options ($0.75) raised $5M and
piggyback options ($1.25) could potentially raise an additional $25M before expiry
29 May 2026
8
A T
Bisantrene’s history of clinical success
T H E
Acute Myeloid Leukaemia
471 patients across 9 Phase 2 & 3
clinical trials
Approved in France in 1988, but Lederle (Pfizer) ended
commercial development of bisantrene due to solubility issues
Less toxic than standard-of-care
doxorubicin
- reduced myelosuppression
- reduced alopecia (hair loss)
- no cardiac failures
Complete response rates above 40% as a salvage agent for
Acute Myeloid Leukaemia (AML)
O F
C A N C E R
C A R E
Phase 3. Overall patient survival
greater in bisantrene treated
patients (HR 0.92 95%CI = 0.7-1.21)
H E A R T
Breast cancer 1
Bisantrene cured two French girls with r/rAML in the 1980 &
90s. Both women are alive today and have their own families
Complete responses with bisantrene in paediatric and adult Acute Myeloid Leukaemia patients
80%
70%
60%
50%
40%
30%
20%
10%
0%
1. Cowan, J. D. et al. . Natl. Cancer Inst. 83, 1077–1084 (1991)
72%
50%
46%
40%
50%
23%
Marty et al 19851 Phase I,
Adult (N=17)
Marty et al 19872 Phase II, Leblanc et al 19943 Phase II,
Adult (N=40)
Pediatric (N=22)
Tosi et al 19894 Phase II,
Adult (N=10)
Bezwoda and Seymour
Spadea et al 19936 Phase II,
19895 Phase II, Adult (N=15)
Adult (N=7)
9
A T
Bisantrene + doxorubicin =
improved anti-cancer activity 1
T H E
H E A R T
O F
Bisantrene shows potent cell-killing activity against a diverse range of human cancers when used alone and in combination with
doxorubicin, the most commonly used anthracycline
85%
C A R E
Increasing potency
C A N C E R
Bisantrene improves doxorubicin anti-cancer activity in
of all cancers2
Bisantrene shows broad anti-cancer activity. The half-maximal inhibitory concentration (IC50) was
determined for bisantrene against 143 cancer cell lines derived from diverse human tumour types.
Boxes show the 25%-75% range, with the line within each box representing the median IC50 value. The
upper and lower edges of the box represent the 75th and 25th percentiles, respectively. Whiskers show
the minimum and maximum IC50 values observed for each cancer cell type.
1. ASX Announcement: 21 September 2023 | 2. 143 cancer cell lines screened.
10
T H E
Vehicle
Doxorubicin
Dox + Bis 1:2
C A R E
Data supports using bisantrene with anthracyclines to protect
the hearts of patients from chemotherapy
Cardiac output of C57BL/6 mice treated with either vehicle control (blue), bisantrene alone (orange),
doxorubicin alone (grey), 1:1 molar ratio doxorubicin + bisantrene (yellow), or 1:2 molar ratio
doxorubicin + bisantrene (red) at Day 0 and Day 42. All mice were dosed intravenously weekly with
either: vehicle control, 7.33 mg/kg bisantrene, 5 mg/kg of doxorubicin, 5 mg/kg of doxorubicin + 3.67
mg/kg of bisantrene, 5 mg/kg of doxorubicin + 7.33 mg/kg of bisantrene. n=12 per group. Error bars =
SEM. **p < 0.01.
Promise of better cancer treatment with reduced side effects
Dox/Bis
Dox
Normal
Strong protection from anthracycline-induced cardiomyopathy
No Fibrosis
1. ASX Announcement: 30 June 2022
Extensive Fibrosis
C A N C E R
Dox + Bis 1:1
Heart protection was achieved using higher levels of
chemotherapy treatment with no extra toxicity observed
O F
Bisantrene
H E A R T
Bisantrene protects the hearts of mice from permanent damage
caused by the anthracycline, doxorubicin
A T
Bisantrene + doxorubicin =
protecting the heart 1
Minimal Fibrosis
In vitro studies in human primary
cardiomyocytes and in vivo studies in mice have
demonstrated cardioprotection for the
bisantrene + doxorubicin combinations,
including increased cardiac function and
reduced fibrosis when compared to doxorubicin
alone
11
H E A R T
•
Created new intellectual property with a long lifespan (20 years)
•
Leveraged new science to understand bisantrene’s anti-cancer and
cardioprotective mechanism of action 2
•
Built on the >1,500 patients’ worth of clinical data across a broad range
of cancer indications, and generated new Phase 2 clinical data in AML
•
RC220 is a new drug product, requiring a full non-clinical
toxicology & safety data package – delivered in June 2024 3
C A R E
RC220 preserves the PK/PD properties of the earlier clinically
validated formulations of bisantrene
C A N C E R
•
O F
Created RC220, a new formulation of bisantrene which is more soluble
and can be delivered intravenously 1
T H E
Race has…
•
A T
Building on bisantrene’s history
RC220 is a clinically and commercially
attractive formulation with long IP life
1. ASX Announcement: 9 November 2023 | 2. ASX Announcement: 21 September 2023 | 3. ASX Announcement 27 June 2024
12
A T
T H E
RC220 cardioprotection clinical program
H E A R T
An ‘all comers’ Bayesian dose escalation Phase 1a/1b trial of RC220 in any solid tumour patient
where anthracycline use is indicated
O F
C A N C E R
Size: 25-50 patients; up to 10 sites in Australia and internationally
Sponsor: Race Oncology
Primary endpoints: Safety & optimal Phase 2 dose
Exploratory endpoints: Standard & advanced cardiovascular markers including VO2Peak; m6A RNA levels and
anti-cancer efficacy
Start: First patient H2 CY2024
Timeline: 12–18 months due to Bayesian design uncertainty around total patient number (patient recruitment)
C A R E
Cohort extension (Phase 1b) in patient sub-groups to optimise bisantrene dosage in different drug
combination settings
Expands market potential of bisantrene beyond breast cancer to all cancers where anthracyclines are
used
Effect of bisantrene on the m6A RNA system will be collected by using a lead-in dose of bisantrene
given 7 days prior to the first anthracycline combination dose – provides ‘clean’ PK/PD, m6A RNA &
single-agent anti-cancer efficacy data
Cost: A$9 million, fully funded (based on 40 patients)
1. Foulkes SJ et al. Circulation, 2023
VO2Peak offers a clinically
relevant endpoint that can
provide clear evidence of
cardioprotection and
improvement in patient
Quality of Life 1
13
A T
Clinical pipeline
T H E
H E A R T
O F
IND
enabling
Sponsor
Discovery
Acute Myeloid Leukaemia
Chaim Sheba
Medical
Centre,
Israel
Phase 2
RC220
Cardioprotection + m6A RNA + anticancer efficacy - solid tumours
Race
Oncology
Phase 1a/b
H2 CY24
RC220
Acute Myeloid Leukaemia
Investigator
sponsored3
Phase 1/2
H2 CY24
m6A RNA
molecule
development
Next generation bisantrene
Race
Oncology
Preclinical
RC110
Phase 1
Phase 2
Phase 3
Next milestone
In final stages of trial
2026
C A R E
Indication
C A N C E R
Asset
Ethics / governance approvals
First patient dosed
Confirmation of trial
Preliminary results
14
US$1.5b
US$7b
C A N C E R
cardioprotection + anti-cancer2
O F
doxorubicin - 20231
H E A R T
Annual revenue bisantrene
T H E
Annual revenue generic
A T
Bisantrene Market Potential – World
C A R E
Note: Forecasted revenue reflect
a 50% reduction to the physicianstated adoption rate
USD$100 base price/cycle for 4 cycles
1. https://www.theinsightpartners.com/reports/doxorubicin-market
2. Triangle Insights (ASX Announcement: 14 April 2023)
USD$15,000 base price/cycle for 4 cycles with a 3% yearly
net price increase after launch
15
T H E
Distinguished Oncologist Daniel Von
Hoff Joins as Consultant
Additional preclinical results on
bisantrene mechanism of action
Proposal received for investigator led
study of RC220 in AML patients
Ethics submission for Phase 1a/1b
trial in solid tumours
File Investigational New Drug (IND)
application with US Food and Drug
Administration for RC220
cGMP RC220 manufacturing
campaign completes
Governance approval for Phase 1a/1b
trial in solid tumours
First patient treated in Phase 1/2 AML
study
Leading cardiorespiratory expert,
A/Prof Erin Bowden joins SAB
First patient treated in the RC220
solid tumour (all comers) Phase 1a/b
Trial
Initial results from RC220 Phase 1
solid tumour trial
cGMP RC220 released by Ardena for
use in human clinical trials
Updates on new molecules to target
the m6A RNA pathway
Bisantrene shows potent anti-cancer
activity in AML models
Publication of results from Sheba
Phase 2 clinical study in AML
Completion of RC220 non-clinical
safety and toxicology studies
Updates on clinical trial progress for
RC220 cardioprotection study
Appoints George Clinical as CRO
Commence Phase 1/2 AML study
1. All dates are estimates and subject to change
C A R E
Interim results released from Sheba 2
study of bisantrene RC110 in AML
patients – 40% response rate
C A N C E R
H1 CY2025
O F
H2 CY2024
H E A R T
H2 CY2023 / H1 CY2024
A T
Recent & upcoming milestones1
16
H E A R T
O F
C A N C E R
C A R E
Solves real & significant health problem –
cardiovascular damage caused by
chemotherapy, a rising issue due to ageing
population and post-cancer longevity
T H E
Bisantrene – derisked & clinically proven
anti-cancer drug offering ~80% chance of
success - not ~3% common in oncology
A T
Key highlights of Race Oncology
Bisantrene builds on a major existing market
of 20m anthracycline doses/year, potential
sales >US$5B/year
Low-cost development with an opportunity
for a rapid pathway to market via the FDA
accelerated approval process from Phase 2
Management invested with proven technical,
deal & ASX track record
17
Questions
Race Oncology
A T
T H E
H E A R T
O F
C A N C E R
C A R E
18
Share your feedback
Discover